Safety and Effectiveness of CGB-500 Topical Ointment with 0.5% and 1% Tofacitinib for the Treatment of Atopic Dermatitis: a Randomized, Dose-Ranging, Vehicle-Controlled, Double-Blind Trial
Latest Information Update: 12 Feb 2025
Price :
$35 *
At a glance
- Drugs Tofacitinib (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors CAGE Bio
- 15 Jan 2025 New trial record
- 09 Jan 2025 CAGE Bio announced the initiation of a Phase 2b dose-ranging trial in CGB-500.